- Home
- ACLS vs APLS Comparison
ACLS vs APLS Comparison
Compare ACLS & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACLS | APLS |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ACLS | APLS |
|---|---|---|
| Price | $90.14 | $17.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | ★ $101.50 | $31.65 |
| AVG Volume (30 Days) | 676.2K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | ★ 3.80 | 0.20 |
| Revenue | $839,048,000.00 | ★ $1,003,782,000.00 |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $7.91 | $18.21 |
| P/E Ratio | ★ $25.62 | $84.90 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $40.40 | $16.10 |
| 52 Week High | $102.93 | $30.48 |
Technical Indicators
Market Signals| Indicator | ACLS | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 29.85 |
| Support Level | $78.24 | N/A |
| Resistance Level | $93.22 | $20.65 |
| Average True Range (ATR) | 4.55 | 0.65 |
| MACD | 1.13 | -0.05 |
| Stochastic Oscillator | 42.38 | 7.89 |
Price Performance
Historical ComparisonAbout ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).